Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation

European Journal of Nuclear Medicine

Volumn 25, Issue 10, 1998, Pages 1429-1434

  Crippa, Flavio ^a   Seregni, Ettore ^a   Agresti, Roberto ^a   Chiesa, Carlo ^a   Pascali, Claudio ^a   Bogni, Anna ^a   Decise, Donatella ^a   De Sanctis, Vinicio ^a   Greco, Marco ^a   Daidone, Maria Grazia ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Fluorine 18 fluorodeoxyglucose; PET; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN P53; STEROID RECEPTOR; CELL SURFACE RECEPTOR; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; THYMIDINE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT PLANNING; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; THYMIDINE; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031593949     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050319     Document Type: Article

References (27)

1. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
2. Tse NY, Hoh CK, Randall AH, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
3. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
4. Adler LP, Crowe JP, Al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [H-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
5. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21: 280-283.
6. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
7. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
8. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23: 618-623.
9. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
10. 18F]FDG positron emission tomography (PET) in the presurgical staging of the axilla in breast cancer: comparison between PET and postoperative pathology. J Nucl Med 1998; 39: 4-8.
11. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxy-glucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
12. Eberlein TJ. Current management of carcinoma of the breast. Ann Surg 1994; 2: 121-136.
13. Schomburg A, Bender H, Reichel C, et al. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 1996; 23: 571-574.
14. Silvestrini R, Daidone MG, Valagussa P, et al. Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1165-1171.
15. 3H]-thymidine labelling index in breast cancer. Cell Prolif 1991; 21: 437-445.
16. Bombardieri E, Seregni E, Daidone MG, et al. p53 accumulation in primary breast cancer: a comparison between immunohistochemistry and a novel luminometric immunoassay. Tumour Biol 1998; 19: 12-18.
17. Higashi K, Clavo AC, Wahl R. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414-419.
18. Kubota K, Kubota K, Yamada S. FDG accumulation in tumour tissue. J Nucl Med 1993; 34: 419-421.
19. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-261.
20. Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
21. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991; 10: 85-91.
22. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
23. Levine AJ, Momad J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453.
24. de Witte HH, Foekens JA, Lennerstrand J, et al. Prognostic significance of TP53 accumulation in human breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 1996; 69: 125-130.
25. Alred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
26. Barbareschi M. Prognostic value of immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9,000 patients. Appl Immunohistochem 1996; 4: 106-116.
27. Berns EMJJ, Klijn JGM, Smid M, et al. TP53 and myc gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosom Cancer 1996; 16: 170-179.